BioNTech SE - ADR Stock News

Die Aktie schwankt, doch die Strategie ist klar: BioNTech setzt auf mRNA-Innovationen – und CureVac soll das Tempo weiter erhöhen.

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that  BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology an...

Eine Übernahmeofferte von Biontech US09075V1026 hat die Aktien von Curevac NL0015436031 am Donnerstag im vorbörslichen US-Handel um mehr als ein Drittel nach oben getrieben.

MAINZ - Großes Zusammenrücken in der deutschen Biotech-Branche: Das Mainzer Pharmaunternehmen Biontech US09075V1026 will den Rivalen Curevac NL0015436031 aus Tübingen übernehmen.